BARNETT INTERNATIONAL ANNOUNCES SPRING SEMESTER OF CLINICAL RESEARCH TRAINING PROGRAMS
MEDIA, PA, January 17, 2000 — Barnett International Corporation, a subsidiary of PAREXEL International Corporation (Nasdaq:PRXL), announced today a new semester of clinical research training programs being offered at the following universities: Villanova University, Georgetown University, University of North Carolina, Northwestern University, Boston College, and the University of San Diego. The programs are titled "Developing Clinical Data Management Skills", "Developing Clinical Research Associate Skills", and "Developing Clinical Research Coordinator Skills". The curriculum is designed to open doors for new career opportunities in clinical research and the pharmaceutical industry. These courses begin between February 26 and April 1, 2000 and last for 6-12 weeks depending on the university.
The "Developing Clinical Data Management Skills" program helps pharmaceutical industry employees who are responsible for reviewing clinical data generated in investigational drug trials. The course covers coding the data for database entry, editing the data for accuracy and completeness, and finalizing the data for statistical analysis and review. "Developing Clinical Research Associate Skills" is geared to professionals who monitor clinical investigations of experimental drugs and medical devices for pharmaceutical/biotechnical and medical device manufacturers. The "Developing Clinical Research Coordinator Skills" program reviews and discusses the Clinical Research Coordinator’s (CRC) role in the day-to-day management of clinical trials and the CRC’s close working relationships with the investigating physician and study sponsor.
According to the latest data from the U.S. Department of Labor, the demand for qualified Clinical Research Associates, Clinical Research Coordinators, and Clinical Data Managers is expected to nearly double over the next ten years. Barnett offers these new courses in response to the industry’s growing need for such professionals.
Barnett International is a recognized industry leader in pharmaceutical consulting, education and training, specializing in such areas as technology, performance benchmarking, clinical training, knowledge management, industry conferences, and the publishing of drug development texts and journals. PAREXEL is a leading contract research, medical marketing, consulting services organization providing a broad range of knowledge-based outsourcing to the worldwide pharmaceutical, biotechnology, and medical device industries and to the academic community. Over the past fifteen years, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training, publishing and other drug development consulting services. PAREXEL is the first major CRO to develop a pediatric clinical research initiative to respond to the recently enacted FDA Modernization Act and the Final Pediatric Rule. Headquartered near Boston, MA, PAREXEL has approximately 4,400 employees in 46 locations throughout 29 countries around the world.
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future growth and customer demand. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that might cause such a difference include, but are not limited, to risks associated with: loss or delay of large contracts; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses; government regulation of certain industries and clients; competition and consolidation within the industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. These factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 1999.